Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?
- PMID: 24472743
- DOI: 10.1097/QAD.0000000000000096
Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?
Abstract
Objective: To assess changes over time in neuropsychological test results (NPr) and risk factors among a regularly followed HIV-infected patient population.
Methods: Prospective cohort of HIV-infected patients randomly selected to undergo neuropsychological follow-up. Test score was adjusted for age, sex and education. Patients were divided into five groups: normal tests, neuropsychological deficit (one impaired cognitive domain), asymptomatic neurocognitive disorders (ANIs), mild neurocognitive disorders (MNDs) and HIV-associated dementia (HAD). Demographic and background parameters including CSF drug concentration penetration effectiveness (CPE) score 2010 were recorded. Changes in NPr and associated risk factors were analyzed.
Results: Two hundred and fifty-six patients underwent neuropsychological tests and 96 accepted follow-up approximately 2 years later. The groups were comparable. Upon neuropsychological retesting, six patients improved, 31 worsened and 59 were stable. The proportion of patients with HIV-associated neurocognitive disorders (HANDs) rose from 26 to 45%, with ANIs and MNDs still mostly represented. Most patients initially diagnosed with HANDs remained stable, five of 25 showed clinical improvement and three of 25 deteriorated. Of 33 patients with normal tests, four deteriorated, whereas 24 of 38 with initial neuropsychological deficit had poorer NPr, and contributed most of the new HAND cases. Patients with clinical deterioration had a lower CPE score both at inclusion (6.9 vs. 8.1; P = 0.005) and at the end of follow-up (7.2 vs. 7.8; P = 0.08) than those with improved or stable performance. This was confirmed by multivariate analysis.
Conclusion: Patients with higher CPE scores upon inclusion and at the end of follow-up were at lower risk of clinical worsening, suggesting that combination antiretroviral therapy with better CSF penetration could protect against cognitive deterioration.
Similar articles
-
A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.J Neurovirol. 2017 Apr;23(2):216-225. doi: 10.1007/s13365-016-0490-z. Epub 2016 Nov 4. J Neurovirol. 2017. PMID: 27815816
-
HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.S Afr Med J. 2013 Sep 18;103(10):758-62. doi: 10.7196/samj.6677. S Afr Med J. 2013. PMID: 24079630
-
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.Neurology. 2011 Apr 19;76(16):1403-9. doi: 10.1212/WNL.0b013e31821670fb. Neurology. 2011. PMID: 21502598
-
Neurocognitive impairment and neuroCART.Curr Opin HIV AIDS. 2011 Jul;6(4):303-8. doi: 10.1097/COH.0b013e3283477c46. Curr Opin HIV AIDS. 2011. PMID: 21546833 Review.
-
Protease inhibitor monotherapy and the CNS: peace of mind?J Antimicrob Chemother. 2011 Sep;66(9):1954-62. doi: 10.1093/jac/dkr229. Epub 2011 Jun 13. J Antimicrob Chemother. 2011. PMID: 21672918 Review.
Cited by
-
Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infection.HIV Med. 2015 Jul;16(6):355-61. doi: 10.1111/hiv.12220. Epub 2015 Jan 21. HIV Med. 2015. PMID: 25604610 Free PMC article.
-
Neurocognitive Impairment and Associated Genetic Aspects in HIV Infection.Curr Top Behav Neurosci. 2021;50:41-76. doi: 10.1007/7854_2018_69. Curr Top Behav Neurosci. 2021. PMID: 30523615
-
A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals.Clin Infect Dis. 2014 Dec 1;59(11):1627-34. doi: 10.1093/cid/ciu640. Epub 2014 Aug 11. Clin Infect Dis. 2014. PMID: 25114032 Free PMC article.
-
Treating HIV Infection in the Central Nervous System.Drugs. 2017 Feb;77(2):145-157. doi: 10.1007/s40265-016-0678-9. Drugs. 2017. PMID: 28070871 Review.
-
Neurologic Complications in Treated HIV-1 Infection.Curr Neurol Neurosci Rep. 2016 Jul;16(7):62. doi: 10.1007/s11910-016-0666-1. Curr Neurol Neurosci Rep. 2016. PMID: 27170369 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous